API Anti Inflammation CAS 80214-83-1 Roxithromycin powder

API Anti Inflammation CAS 80214-83-1 Roxithromycin powder

The Introductction of Roxithromycin

      Roxithromycin, a western medicine, is a new generation of macrolide antibiotics, mainly acting on gram-positive bacteria, anaerobic bacteria, chlamydia and mycoplasma. Its antibacterial effect in vitro is similar to erythromycin, and its antibacterial effect in vivo is 1~4 times stronger than erythromycin.

The Application & Roxithromycin

1. Roxithromycin is suitable for the treatment of pharyngitis and tonsillitis caused by Streptococcus pyogenes.

2. Roxithromycin is indicated for the treatment of sinusitis, otitis media, acute bronchitis and acute attacks of chronic bronchitis caused by sensitive bacteria.

3. Roxithromycin is indicated for the treatment of pneumonia caused by Mycoplasma pneumoniae or Chlamydia pneumoniae; urethritis and non-specific urethritis (cervicitis) caused by Chlamydia trachomatis.

4. Roxithromycin is indicated for the treatment of skin soft tissue infections caused by sensitive bacteria. Genitourinary system infections.

Whatsapp: +86 15202961574

         Roxithromycin is a new generation of macrolide antibiotics, which is a semi synthetic 14 membered macrolide drug. Its mechanism of action is the same as that of erythromycin. It mainly combines with bacterial 50S ribosomal subunit, and inhibits bacterial protein synthesis by blocking peptide transfer and mRNA transfer, thus playing an antibacterial role. It is characterized by rapid entry into macrophages, lung cells, alveoli and polymorphonuclear leukocytes. The antibacterial spectrum of roxithromycin is similar to that of erythromycin. Its antibacterial effect in vitro is similar to that of erythromycin, and its antibacterial effect in vivo is 1~4 times stronger than that of erythromycin.

          The effect of roxithromycin on gram-positive bacteria was slightly worse than that of erythromycin, and on legionella pneumophila was stronger than that of erythromycin. The antimicrobial effect of Chlamydia pneumoniae, Mycoplasma pneumoniae and Ureaplasma urealyticum is similar to or slightly stronger than erythromycin. Roxithromycin has strong antibacterial activity against Staphylococcus aureus (except MRSA), streptococci (including Type A, B, C streptococci and Streptococcus pneumoniae, except Type G and Enterococcus), Corynebacterium, Listeria, Moraxella catarrhalis (Catarrhococcus), Legionella, etc; It also has certain effects on oral Bacteroides, Bacteroides niger, digestive coccus, digestive streptococcus, propionibacterium acnes and other anaerobic bacteria, as well as toxoplasma encephalitis, chlamydia, mycoplasma, ureaplasma urealyticum, treponema pallidum, etc; It has weak effect on helicobacter, gonococcus, meningococcus, pertussis bacillus, etc.

The COA of Roxithromycin

HNB Biotech company details